Thus it is conceivable that pathogens control and modulate one, more or even all effector functions of the activated host complement cascade [[7, 8]]. A series of recent studies, in combination with past reports summarized in [[6]] have identified an important role for the activated complement cascade as a central defense element of the human innate immune response [[3, 9-12]]. Predominantly, the C3 effector level of Trichostatin A order the cascade is considered important for this immediate, first-line response. The C3 effector response is induced by the enzymatic cleavage of the soluble human plasma protein C3 to the effector molecules C3a and C3b (Fig. 1). The activation peptide C3a has antifungal as well as bactericidal activity

and displays chemotactic and inflammatory activities [[13]]. Newly formed C3b is deposited onto a nearby fungal surface and — when not properly controlled and inactivated — surface-deposited C3b initiates the complement amplification loop [[14]]. This loop serves to form additional C3 convertases, which cleave soluble C3 to generate more effector molecules. As a consequence more antifungal

C3a is generated and the fungal surface becomes decorated with C3b. This opsonization is aimed at recognition, engagement, and phagocytosis of the microbial intruder by human immune effector cells, particularly macrophages and neutrophils. Cheng et al. [1], in this issue of the European Journal of Immunology, now demonstrate that Candida infection also activates Lumacaftor cost complement via the C5 level, a powerful inflammatory response that acts downstream of C3 (Fig. 1). The C5 complement effector level is reached by the generation of C5 convertases that cleave the plasma protein C5 into C5a and C5b. C5a is a strong inflammatory component that induces a proinflammatory host response and recruits and activates host immune effector cells including macrophages, neutrophils eosinophils, basophils and mast

cells, and other inflammatory cells [[14]]. Newly formed Sorafenib molecular weight C5b can subsequently initiate and trigger the terminal pathway of complement, which forms the membrane inserting terminal complement complex, (TCC), which is also termed as MAC (membrane attack complex). The article by Cheng et al. [1] now shows that C5a is generated in response to the fungal pathogen C. albicans and induces an inflammatory cytokine response in PBMCs. The inflammatory pathway offers a new concept for understanding the role of the host’s innate immune recognition and defense against C. albicans. Interestingly, the authors study this aspect of this immunological arms race from both sides, from side of the human host and also from side of the fungal pathogen. On the host side, the authors demonstrate a complement-mediated inflammatory cytokine response by PBMCs; furthermore, by identifying host genetic susceptibility factors, they define which step of the cascade mediates this response.